Impax Asset Management Group PLC Vertex Pharmaceuticals Inc Transaction History

Impax Asset Management Group PLC

$23 Billion
Q3 2024

A detailed history of Impax Asset Management Group PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Impax Asset Management Group PLC holds 7,433 shares of VRTX stock, worth $3.35 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

7,433

Previous 7,433 -0.0%

Holding current value

$3.35 Million

Previous $3.46 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	SELL	$460.0 - $505.78 $21.1 Million - $23.2 Million	-45,963 Reduced 86.08%	7,433 $3.46 Million
Q2 2024 Nov 08, 2024	BUY	$392.81 - $485.53 $18.1 Million - $22.3 Million	45,963 Added 618.36%	53,396 $25 Million
Q2 2024 Aug 05, 2024	SELL	$392.81 - $485.53 $5.64 Million - $6.97 Million	-14,362 Reduced 21.2%	53,396 $25 Million
Q1 2024 Apr 30, 2024	SELL	$407.69 - $446.08 $6.75 Million - $7.38 Million	-16,555 Reduced 19.64%	67,758 $28.3 Million
Q4 2023 Jan 26, 2024	SELL	$343.0 - $410.68 $163 Million - $195 Million	-473,825 Reduced 84.89%	84,313 $34.3 Million
Q3 2023 Nov 07, 2023	SELL	$338.18 - $362.46 $8.72 Million - $9.34 Million	-25,782 Reduced 4.42%	558,138 $194 Million
Q2 2023 Aug 07, 2023	SELL	$314.42 - $351.91 $56.1 Million - $62.8 Million	-178,427 Reduced 23.4%	583,920 $205 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $471,294 - $537,638	-1,664 Reduced 0.22%	762,347 $240 Million
Q4 2022 Feb 09, 2023	BUY	$285.76 - $321.48 $18.9 Million - $21.3 Million	66,278 Added 9.5%	764,011 $221 Million
Q3 2022 Nov 08, 2022	SELL	$273.83 - $305.53 $6.35 Million - $7.09 Million	-23,201 Reduced 3.22%	697,733 $202 Million
Q2 2022 Aug 11, 2022	SELL	$234.96 - $292.55 $32.8 Million - $40.9 Million	-139,738 Reduced 16.24%	720,934 $203 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $38.1 Million - $44.9 Million	-172,183 Reduced 16.67%	860,672 $225 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $7.41 Million - $9.36 Million	-41,881 Reduced 3.9%	1,032,855 $227 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $57.9 Million - $64.8 Million	319,209 Added 42.25%	1,074,736 $195 Million
Q2 2021 Aug 05, 2021	BUY	$187.49 - $221.1 $125 Million - $147 Million	666,559 Added 749.21%	755,527 $152 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $2.77 Million - $3.23 Million	13,396 Added 17.73%	88,968 $19.1 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $2.15 Million - $2.87 Million	10,381 Added 15.92%	75,572 $17.9 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $4.77 Million - $5.65 Million	18,641 Added 40.05%	65,191 $17.7 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $1.38 Million - $1.81 Million	-6,121 Reduced 11.62%	46,550 $13.5 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $1.57 Million - $1.95 Million	7,880 Added 17.59%	52,671 $12.5 Million
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $78,020 - $104,789	468 Added 1.06%	44,791 $9.81 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $6.6 Million - $7.43 Million	39,709 Added 860.62%	44,323 $7.51 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $73,086 - $84,524	444 Added 10.65%	4,614 $846,000
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $115,102 - $136,874	703 Added 20.28%	4,170 $767,000
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $10,026 - $12,685	66 Added 1.94%	3,467 $575,000
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $570,449 - $655,508	3,401 New	3,401 $656,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Impax Asset Management Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Impax Asset Management Group PLC with notifications on news.

Account

Impax Asset Management Group PLC Vertex Pharmaceuticals Inc Transaction History